Hepatologie 2019

Christian Ruis – Gastroenterologie – Spital Thun

PBC - Primär Biliäre Cholangitis

- Früher: Primär Biliäre Cirrhose





Primär Biliäre Cholangitis

- Bisher Therapie mit Ursodesoxycholsäure





Poupon RE, Poupon R, Balkau B, and the UDCA-PBC Study Group, N Engl J Med 1994; 330:1342

NEJM 08/2016, POISE-Studie

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

F. Nevens, P. Andreone, G. Mazzella, S.I. Strasser, C. Bowlus, P. Invernizzi, J.P.H. Drenth, P.J. Pockros, J. Regula, U. Beuers, M. Trauner, D.E. Jones, A. Floreani, S. Hohenester, V. Luketic, M. Shiffman, K.J. van Erpecum, V. Vargas, C. Vincent, G.M. Hirschfield, H. Shah, B. Hansen, K.D. Lindor, H.-U. Marschall, K.V. Kowdley, R. Hooshmand-Rad, T. Marmon, S. Sheeron, R. Pencek, L. MacConell, M. Pruzanski, and D. Shapiro, for the POISE Study Group*

- Preis
- Juckreiz



***p<0.0001 vs. placebo; p values obtained using Cochran-Mantel-Haenszel stratified by randomization strata factor; Titration OCA group: 5 mg OCA for 6 months then titrated to 10 mg OCA if tolerated & ALP ≥1.67x ULN or bilirubin >ULN.
Adapted from Nevens F, et al. Presented at AASLD, 65th Scientific Session; 2014; Boston, MA (Poster 295).

NEJM 07/2018, BEZURSO-Studie

ORIGINAL ARTICLE

A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis

C. Corpechot, O. Chazouillères, A. Rousseau, A. Le Gruyer, F. Habersetzer, P. Mathurin, O. Goria, P. Potier, A. Minello, C. Silvain, A. Abergel, M. Debette-Gratien, D. Larrey, O. Roux, J.-P. Bronowicki, J. Boursier, V. de Ledinghen, A. Heurgue-Berlot, E. Nguyen-Khac, F. Zoulim, I. Ollivier-Hourmand, J.-P. Zarski, G. Nkontchou, S. Lemoinne, L. Humbert, D. Rainteau, G. Lefèvre, L. de Chaisemartin, S. Chollet-Martin, F. Gaouar, F.-H. Admane, T. Simon, and R. Poupon

Bezafibrat – PPAR-Agonist

(agonists of peroxisome proliferator–activated receptors)



Bezafibrat



BEZURSO

- Unzureichendes Ansprechen auf Ursodesoxycholsäure bei PBC

UDC + Placebo < > UDC + Bezafibrat 400 mg/d

- 24 Monate -

Normalisierung Leberwerte / Bilirubin



- **Normale AP** 67 % vs. 2 %
- **Fibroscan** - 15 % vs. + 22 %

Sicherheit

Event	Bezafibrate Group (N=50)	Placebo Group (N=50)
	no. of patients with event (%)	
Any adverse event	43 (86)	45 (90)
Arthralgia	7 (14)	11 (22)
Myalgia	10 (20)	5 (10)
Nasopharyngitis	9 (18)	10 (20)
Bronchitis	4 (8)	9 (18)
Depressive mood	7 (14)	8 (16)
Abdominal pain	7 (14)	6 (12)
Pruritus	4 (8)	7 (14)
Diarrhea	1 (2)	6 (12)
Flulike syndrome	5 (10)	5 (10)
Any serious adverse event	14 (28)	12 (24)
Aminotransferase level >5x ULN	3 (6)	1 (2)
Creatine kinase level >5x ULN	1 (2)	0
Creatinine increase with worsening stage of chronic kidney disease	1 (2)	0

Fettlebererkrankung



Gene für NAFLD und ALD



Buch et al., Nature Genetics 2015, Kozlitina et. al. Nature Genetics 2014

Risikogene für Fettleber



Buch et al., unpublished data